Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets (2016 - 2025)

Ani Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $753.1 million for Q4 2025.

  • For Q4 2025, Current Assets rose 42.51% year-over-year to $753.1 million; the TTM value through Dec 2025 reached $753.1 million, up 42.51%, while the annual FY2025 figure was $753.1 million, 42.51% up from the prior year.
  • Current Assets for Q4 2025 was $753.1 million at Ani Pharmaceuticals, up from $698.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $753.1 million in Q4 2025 and bottomed at $182.8 million in Q1 2021.
  • The 5-year median for Current Assets is $478.3 million (2023), against an average of $437.1 million.
  • The largest annual shift saw Current Assets soared 88.92% in 2021 before it decreased 0.79% in 2025.
  • A 5-year view of Current Assets shows it stood at $321.8 million in 2021, then increased by 6.99% to $344.3 million in 2022, then soared by 50.99% to $519.8 million in 2023, then increased by 1.66% to $528.5 million in 2024, then soared by 42.51% to $753.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Current Assets are $753.1 million (Q4 2025), $698.4 million (Q3 2025), and $602.6 million (Q2 2025).